Genelux Corporation
GNLX · NASDAQ
Market closed$2.87$0.050000 (+1.77%)After hours $2.87 · 0.00%
Key statistics
Previous close$2.82
Open$2.82
Day high$2.88
Day low$2.82
52-week high$8.54
52-week low$2.29
Market cap107.96M
Volume77.17K
Average volume172.06K
P/E ratio-3.38
Forward P/E—
EPS-0.85
Dividend yield0.00%
Market context
Why it moved
GNLX edged modestly higher in low-volume trading, with no specific company catalyst identified, suggesting the slight uptick reflects broader sector sentiment and continued investor confidence supported by the stock's strong 52-week performance and a "Strong Buy" consensus with a significantly higher average analyst price target.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · June 30, 2026Genelux says Olvi-Vec may reawaken platinum response in ovarian cancerGlobeNewswire · May 7, 2026Genelux Corporation Reports First Quarter Financial Results and Provides Business UpdatesQuiver Quantitative · March 19, 2026Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership AppointmentSeeking Alpha · November 13, 2025Genelux: Oncolytic Virus Player Near Phase 3 Finish Line, But Correction Likely (GNLX) Benzinga · June 30, 2026Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In Heavily Pretreated Patients With Platinum-R/R Ovarian Cancer Benzinga · March 20, 2026Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $20 Benzinga · March 19, 2026Genelux Q4 EPS $(0.24) Misses $(0.21) Estimate Mt Newswire · January 8, 2026Genelux Shares Fall After $20 Million Stock Offering Priced Benzinga · January 8, 2026Genelux Prices ~$20M Public Offering Of 6.67M Shares At A Price Of $3/Share Benzinga · January 7, 2026Genelux Corporation Announces Proposed Public Offering Of Common Stock; No Terms Disclosed Benzinga · January 5, 2026Genelux Announces Interim Results From Two Ongoing Trials, Phase 1b/2 SCLC And Phase 2 VIRO-25, Evaluating Systemic Administration Of Olvi-Vec In Patients With Progressive SCLC And NSCLC Mt Newswire · January 2, 2026Genelux Names Jason Litten as Chief Medical Officer